Point of Care Diagnostics Market to Hit USD 78.11 Billion by 2030; Technological Innovations In POC Diagnostic to Propel Market Growth

The global point of care diagnostics market size is estimated to display strong growth by reaching USD 78.11 billion by 2030. Fortune Business Insights™ in its report titled “Point of Care Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Product (Blood Glucose Monitoring, Infectious Disease Testing, Cardiometabolic Disease Testing, Pregnancy & Fertility Testing, Hematology Testing, and Others), By Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, and Others), By End-user (Hospital Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, and Homecare/Self-Testing), and Regional Forecast, 2023-2030” observes that the market size in 2022 stood at USD 43.93 billion and is expected to reach USD 45.85 billion in 2023. The market is expected to witness a strong CAGR of 7.9% during 2023-2030. In point of care testing, the sample does not need to send to a laboratory for testing. The device or kit is used for the production of rapid and reliable results that further aid in the rapid diagnosis of acute and chronic diseases. Technological innovations in the diagnostic kits is driving the market growth.

Boditech Med Inc. Signed With Sphingotec Gmbh For Development And Commercialization For AFIAS And Ichroma Point Of Care Platforms

In November 2022, Boditech Med Inc. signed a license agreement with Sphingotec GmbH where Boditech Med aims to develop and commercialize clinical tests for its AFIAS and ichroma Point of Care platforms. Proenkephalin A 119-159 (penKid) is a biomarker for real-time assessment of kidney function developed by Sphingotec GmbH. 

Increasing Government Initiatives For The Rapid Development Of Diagnostic Test Kits During The Pandemic Supported Market Growth

Increasing government initiatives for the rapid development of diagnostic test kits and demand for such diagnostic devices at the time of COVID-19 pandemic. This led to a significant surge in the revenue of the manufacturers, thus, contributing to significant market growth in the years 2021 and 2022. This led to many companies increase their focus on developing and manufacturing diagnostic tests against the SARS-CoV-2 virus. For instance, in December 2021, F. Hoffmann-La Roche Ltd launched the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting CE Mark.

Penetration Of Decentralized Healthcare Systems To Drive Market Growth

Penetration of decentralized healthcare systems to drive point of care diagnostics market growth. Increased in the number of testing due to their rapid results for accurate and quick results and take suitable treatment decisions. A shift from centralized point-of-care testing to decentralized testing for chronic and infectious and chronic has resulted in convenient access for patients to these diagnostics. The adoption of rapid diagnostic testing is related to an increase in decentralized settings as it enables easy accessibility of medical devices and eliminates the need for transportation.

Strong Focus On Developing Point Of Care Testing Devices Pertaining To Incorporating Newer Technologies

The market has various players such as Abbott, F. Hoffman-La Roche AG, and Danaher (Cepheid Inc.) which accounted for the majority market share. In March 2022, Digital Diagnostics entered into a long-term partnership with Baxter International Inc. for combining Welch Allyn RetinaVue 700 Imager and IDx-DR autonomous AI software to detect diabetic retinopathy at the point of care. Other major players such as bioMérieux and Becton Dickinson and Company (BD) have a strong focus on developing point of care testing devices pertaining to incorporating newer technologies such as nanotechnology, Artificial Intelligence, etc.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/point-of-care-diagnostics-market-101072

Key Industry Development

• September 2022: QuantuMDx Group Ltd. announced a collaboration deal with Sansure Biotech which is aimed to accelerate the commercialization of the Q-POC platform and its assays in China.

List of Key Companies Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd (Switzerland)


• Thermo Fisher Scientific Inc. (U.S.)


• Abbott Laboratories (U.S.)


• Quest Diagnostics Incorporated (U.S.)


• BD (U.S.)


• bioMérieux SA (France)


• Cardinal Health, Inc. (U.S.)


• Cepheid (U.S.)


• Trinity Biotech (Ireland)


• Quidel Corporation (U.S.)


• Bio-Rad Laboratories Inc. (U.S.)

Further Report Findings

• North America dominated the market share due to the availability of favorable reimbursement policies. The market stood at USD 15.14 billion in 2022 due to the intense penetration of advanced point-of-care diagnostics for the detection of various chronic and infectious diseases.


• Europe is set to have the highest CAGR due to the government has invested in R&D activities to strengthen the diagnostics sector pertaining to highly advanced point-of-care diagnostic tests.

Table of Segmentation